AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21226785 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 19592546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin1 mRNA expression in patients with non-small-cell lung cancer
Number of subjects: 26
Study 19592546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin1 mRNA expression in the distal part of the pulmonary vein
Number of subjects: 26
Study 19592546 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Pin1 mRNA expression
Number of subjects: 26
Study 19592546 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Pin1 expression based on pulmonary vessel ligation
Number of subjects: 26
Study 16798652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of deferiprone (L1) daily plus desferrioxamine (DFO) twice weekly
Number of subjects: 49
Study 16798652 — intervention group
Group type: COMPARATOR
Intervention: DFO alone
Number of subjects: 49
Study 16798652 — intervention group
Group type: EXPERIMENTAL
Intervention: L1 only
Number of subjects: 49
Study 15541087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 20
Study 15541087 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream
Number of subjects: 20
Study 11273943 — intervention group
Group type: COMPARATOR
Intervention: 8 mg hyperbaric tetracaine
Number of subjects: 45
Study 11273943 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg hyperbaric tetracaine, 10 microg fentanyl, and 0.2 mg epinephrine
Number of subjects: 45
Study 11273943 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg hyperbaric tetracaine, 10 microg fentanyl, and 0.2 mL saline
Number of subjects: 45
Study 9471147 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic total iron score (TIS)
Number of subjects: 254
Study 9471147 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of heterogeneity
Number of subjects: 254
Study 9471147 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected total iron score (corTIS)
Number of subjects: 254
Study 8387662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 81
Study 8387662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8387662 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 81
Study 8387662 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg (pretreatment)
Number of subjects: 81
Study 3475987 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose droperidol (0.25 mg)
Number of subjects: 0
Study 3475987 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose droperidol (0.5 mg)
Number of subjects: 0
Study 3475987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29412666 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-saturated bulk EmimNTf2
Number of subjects: 2
Study 29412666 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(ether sulfone) SILM with water-saturated RTIL
Number of subjects: 2
Study 29412666 — intervention group
Group type: COMPARATOR
Intervention: Dry EmimNTf2
Number of subjects: 2
Study 28746224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (RM)
Number of subjects: 24
Study 28746224 — intervention group
Group type: COMPARATOR
Intervention: No alveolar recruitment maneuver (non-RM)
Number of subjects: 24
Study 26306650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (n=25)
Number of subjects: 50
Study 26306650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 50
Study 23122597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task group (mental arithmetic task)
Number of subjects: 62
Study 23122597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 21402650 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy for seven weeks
Number of subjects: 28
Study 18482111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA)
Number of subjects: 93
Study 18482111 — intervention group
Group type: COMPARATOR
Intervention: Mandibular non-advancement appliance (MNA)
Number of subjects: 93
Study 18482111 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 93
Study 18482111 — intervention group
Group type: EXPERIMENTAL
Intervention: MAA
Number of subjects: 93
Study 16528186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stimulation plus rehabilitation
Number of subjects: 10
Study 16528186 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation only)
Number of subjects: 10
Study 14733349 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatments (ESW)
Number of subjects: 435
Study 14733349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham control)
Number of subjects: 435
Study 10657406 — intervention group
Group type: EXPERIMENTAL
Intervention: GV150526 (800 mg loading dose followed by 200 mg every 12 hours for 3 days)
Number of subjects: 109
Study 10657406 — intervention group
Group type: EXPERIMENTAL
Intervention: GV150526
Number of subjects: 109
Study 10657406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 9092005 — intervention group
Group type: EXPERIMENTAL
Intervention: Technological advances and socioeconomic changes in health care
Number of subjects: 0
Study 9092005 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of basic research in departments of cardiology
Number of subjects: 0
Study 9092005 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of new technologies in terms of cost-effectiveness
Number of subjects: 0
Study 9092005 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols, recommendations, and consensus
Number of subjects: 0
Study 8422658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine (OP) 16 mg/day for 6 weeks
Number of subjects: 29
Study 8422658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3020227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg q.i.d.)
Number of subjects: 12
Study 3020227 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg q.i.d.)
Number of subjects: 12
Study 3020227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30104729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Advice to consume more vegetables
Number of subjects: 113
Study 30104729 — intervention group
Group type: COMPARATOR
Intervention: Control: Baseline vegetable intake
Number of subjects: 113
Study 30104729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Top vegetable categories
Number of subjects: 113
Study 30104729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Vegetable consumption after 3 months
Number of subjects: 113
Study 30104729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Long-term vegetable consumption
Number of subjects: 113
Study 27289163 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal containing 10 g of extra virgin olive oil (EVOO)
Number of subjects: 30
Study 27289163 — intervention group
Group type: COMPARATOR
Intervention: Meal without extra virgin olive oil (EVOO)
Number of subjects: 30
Study 25281778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin daily
Number of subjects: 640
Study 25281778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study 23816489 — intervention group
Group type: EXPERIMENTAL
Intervention: General health promotion intervention
Number of subjects: 1010
Study 23816489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention
Number of subjects: 1010
Study 23816489 — intervention group
Group type: COMPARATOR
Intervention: General health survey assessment
Number of subjects: 1010
Study 23816489 — intervention group
Group type: COMPARATOR
Intervention: Sexual health survey assessment
Number of subjects: 1010
Study 21499206 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (16 μg administered intravenously before ERCP)
Number of subjects: 869
Study 21499206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 869
Study 19156477 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation correction (AC) with small field of view (SFOV) camera
Number of subjects: 78
Study 19156477 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation correction (AC) with large field of view (LFOV) camera
Number of subjects: 78
Study 19156477 — intervention group
Group type: COMPARATOR
Intervention: No attenuation correction (AC) with SFOV camera
Number of subjects: 78
Study 19156477 — intervention group
Group type: COMPARATOR
Intervention: No attenuation correction (AC) with LFOV camera
Number of subjects: 78
Study 19156477 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation correction (AC)
Number of subjects: 78
Study 19156477 — intervention group
Group type: COMPARATOR
Intervention: No attenuation correction (AC)
Number of subjects: 78
Study 17293736 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator therapy in patients with NYHA class II HF
Number of subjects: 0
Study 17293736 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator therapy in patients with NYHA class III HF
Number of subjects: 0
Study 17293736 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone drug therapy in patients with NYHA class III HF
Number of subjects: 0
Study 17293736 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic medical management
Number of subjects: 0
Study 15228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of beta‐conglycinin (5 g daily)
Number of subjects: 41
Study 15228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of beta‐conglycinin
Number of subjects: 41
Study 10656354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hubs with hub protection boxes
Number of subjects: 137
Study 10656354 — intervention group
Group type: COMPARATOR
Intervention: Hubs with needleless closed connectors
Number of subjects: 137
Study 10656354 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 137
Study 10178672 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-BC/4
Number of subjects: 40
Study 10178672 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-BC/5 (Biopack Compoflex)
Number of subjects: 40
Study 10178672 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-BC/5 (Optipac)
Number of subjects: 40
Study 10178672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling of BCs
Number of subjects: 40
Study 7870963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum + active patch (double active)
Number of subjects: 28
Study 7870963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum + placebo patch (gum only active)
Number of subjects: 28
Study 7870963 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo gum + active patch (patch active)
Number of subjects: 28
Study 7870963 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum + placebo patch (double placebo)
Number of subjects: 28
Study 3488674 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 45
Study 3488674 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 45
Study 3488674 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 31261373 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 50
Study 31261373 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 30541604 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread-embedding acupuncture (TEA), administered once every 2 weeks for 8 weeks (4 sessions total)
Number of subjects: 40
Study 30541604 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture, administered twice per week for 8 weeks (16 sessions total)
Number of subjects: 40
Study 30541604 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 40
Study 30541604 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 40
Study 26856224 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) and PCI
Number of subjects: 1826
Study 24636118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle sessions (GBLS) during prenatal care visits
Number of subjects: 0
Study 24636118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle sessions (GBLS) off-site
Number of subjects: 0
Study 22078221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis treatment in women
Number of subjects: 1000
Study 22078221 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis treatment in men
Number of subjects: 1000
Study 22078221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis treatment in women with bleeding
Number of subjects: 1000
Study 22078221 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis treatment in men with bleeding
Number of subjects: 1000
Study 22078221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis treatment in women without bleeding
Number of subjects: 1000
Study 22078221 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis treatment in men without bleeding
Number of subjects: 1000
Study 19852962 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 200 mg once daily for 5 days (patients)
Number of subjects: 55
Study 19852962 — intervention group
Group type: COMPARATOR
Intervention: TMC435 (various doses) in healthy volunteers
Number of subjects: 55
Study 19852962 — intervention group
Group type: COMPARATOR
Intervention: TMC435 200 mg twice daily or 100, 200, or 400 mg once daily (healthy volunteers)
Number of subjects: 55
Study 19852962 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 (patients)
Number of subjects: 55
Study 17284548 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training (PRT)
Number of subjects: 31
Study 17038828 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory route of measles vaccine administration
Number of subjects: 20
Study 17038828 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory route of measles vaccine administration (for vaccinees over 9 months of age)
Number of subjects: 20
Study 17038828 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory route of measles vaccine administration (Edmonston Zagreb strain)
Number of subjects: 20
Study 17038828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol measles vaccine
Number of subjects: 20
Study 17038828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized EZ vaccine
Number of subjects: 20
Study 17038828 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroresponse among seropositive vaccinees
Number of subjects: 20
Study 11901040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular stimulation (BVS)
Number of subjects: 53
Study 10201304 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency MRI
Number of subjects: 55
Study 10201304 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency MRI after restoration of normal vertebral alignment
Number of subjects: 55
Study 7485344 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 253
Study 7485344 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic therapy)
Number of subjects: 253
Study 2050088 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐Sandoz
Number of subjects: 12
Study 2050088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal‐Sup
Number of subjects: 12
Study 2050088 — intervention group
Group type: EXPERIMENTAL
Intervention: Effercal
Number of subjects: 12
Study 2050088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscal
Number of subjects: 12
Study 2050088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscal Chewable
Number of subjects: 12
Study 6840161 — intervention group
Group type: COMPARATOR
Intervention: Cadralazine (ISF 2469) 7.5 mg
Number of subjects: 24
Study 6840161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (ISF 2469) 15 mg
Number of subjects: 24
Study 6840161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (ISF 2469) 20 mg
Number of subjects: 24
Study 6840161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (ISF 2469) 30 mg
Number of subjects: 24
Study 6840161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30520758 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX203
Number of subjects: 0
Study 30520758 — intervention group
Group type: COMPARATOR
Intervention: IR CD‐LD
Number of subjects: 0
Study 30520758 — intervention group
Group type: COMPARATOR
Intervention: Rytary
Number of subjects: 0
Study 29272208 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-obesity message with message fatigue
Number of subjects: 312
Study 24944864 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced version of EMDR (1-2 hours intervention)
Number of subjects: 50
Study 24944864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 22511836 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT)
Number of subjects: 474
Study 22511836 — intervention group
Group type: EXPERIMENTAL
Intervention: Average signal strength (SS)
Number of subjects: 474
Study 22511836 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative SS change
Number of subjects: 474
Study 19016798 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair) in combination with depigmented SIT (Depigoid)
Number of subjects: 140
Study 19016798 — intervention group
Group type: COMPARATOR
Intervention: SIT alone (Control)
Number of subjects: 140
Study 17329468 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment with cognitive training
Number of subjects: 44
Study 17329468 — intervention group
Group type: COMPARATOR
Intervention: Supported employment alone
Number of subjects: 44
Study 14586662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 0
Study 14586662 — intervention group
Group type: COMPARATOR
Intervention: Gastrostomy tube
Number of subjects: 0
Study 11475707 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Jordan HP510
Number of subjects: 78
Study 11475707 — intervention group
Group type: COMPARATOR
Intervention: Braun Oral‐B D9
Number of subjects: 78
Study 9126228 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening by PSA (Hybritech Tandem E), DRE, and TRUS
Number of subjects: 9600
Study 9126228 — intervention group
Group type: EXPERIMENTAL
Intervention: f-PSA/t-PSA ratio with a cut-off value of 0.20
Number of subjects: 9600
Study 9126228 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE
Number of subjects: 9600
Study 9126228 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS, DRE, and PSA-driven biopsies
Number of subjects: 9600
Study 8198093 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal variceal ligation
Number of subjects: 7
Study 8198093 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 7
Study 3591956 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g protein, 30 g fat, and 30 g carbohydrate (P)
Number of subjects: 5
Study 3591956 — intervention group
Group type: COMPARATOR
Intervention: 150 g carbohydrate, 30 g fat, and 30 g protein (C)
Number of subjects: 5
Study 3591956 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 5
Study 30338793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer patients (experimental group)
Number of subjects: 0
Study 30338793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer tissues (experimental group)
Number of subjects: 0
Study 30338793 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR gene mutations (exon 19 and 21) in cervical cancer patients (experimental group)
Number of subjects: 0
Study 30338793 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR gene mutations correlation with clinical features (experimental group)
Number of subjects: 0
Study 27596559 — intervention group
Group type: EXPERIMENTAL
Intervention: imPACT intervention
Number of subjects: 0
Study 27596559 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25499941 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume consumption (more than 1 time per day)
Number of subjects: 9660
Study 25499941 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume consumption (frequency of consumption quartiles)
Number of subjects: 9660
Study 22070527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine
Number of subjects: 6
Study 22070527 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 6
Study 20971252 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 726
Study 20971252 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with dipyridamole
Number of subjects: 726
Study 20971252 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 726
Study 18972076 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane Lubricant Eye Drops
Number of subjects: 107
Study 18972076 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of Systane Lubricant Eye Drops
Number of subjects: 107
Study 15985559 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment
Number of subjects: 795
Study 15985559 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 795
Study 15985559 — intervention group
Group type: COMPARATOR
Intervention: Control group (H pylori positive)
Number of subjects: 795
Study 14727703 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer gel sock in conjunction with the removable rigid dressing
Number of subjects: 16
Study 14727703 — intervention group
Group type: COMPARATOR
Intervention: Normal removable rigid dressing programme
Number of subjects: 16
Study 10378544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (42 microg per actuation)
Number of subjects: 0
Study 10378544 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oral theophylline (titrated to serum levels of 10 to 20 microg/mL)
Number of subjects: 0
Study 10378544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0